Efficacy and safety study of fixed-dose combination of ceftriaxone-vancomycin injection in patients with various infections.
Pathogens can infect almost all tissues and cause serious infections. Objective was to evaluate efficacy and safety of fixed-dose combination of Ceftriaxone-Vancomycin in patients with various infections. Patients (n=305) suffering from different bacterial infections (serious respiratory tract disease, bronchitis, gastrointestinal tract infections, urinary tract infection, cellulites and meningitis) were enrolled. Patients were randomized into two groups depending on severity of illness. Group A (n=106) and Group B (n=199) patients were given intravenous dose of fixed-dose combination 1.5 g B.D. and 3.0 g B.D. respectively for 3-10 days. Hemoglobin, total leukocyte count, erythrocyte sedimentation rate, urea, creatinine levels serum glutamyl oxaloacetic transaminase and glutamyl pyruvic transaminase activities were recorded before and on completion of the treatment. Most of patients (70%) were cured in seven or less than seven days of the treatment. Significant decrease in total leukocyte count, erythrocyte sedimentation rate levels were observed indicating patients were cured from the infections. No significant alterations were observed in hemoglobin, serum urea, creatinine levels, glutamyl oxaloacetic transaminase and glutamyl pyruvic transaminase activities on completion of treatment. The fixed-dose combination of Ceftriaxone-Vancomycin, is found to be effective in treating various bacterial infections without any toxic effect on liver and kidney. Patients well tolerated the drug without major adverse effects.
Chaudhary
Manu
M
Intellectual Scientific Division, R & D Centre, Venus Remedies Limited, Haryana, India.
Shrivastava
Sanjay Mohan
SM
Sehgal
Rajesh
R
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D001772:Blood Cell Count; D002443:Ceftriaxone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004338:Drug Combinations; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D014508:Urea / Q000097:blood; D014640:Vancomycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D006454:Hemoglobins; D014640:Vancomycin; D002443:Ceftriaxone; D014508:Urea; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase